Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive lipid deposition within the liver parenchyma, and is usually accompanied with obesity, insulin resistance, type 2 diabetes (T2DM), insulin resistance, metabolic syndrome. Recently, NAFLD has been officially renamed metabolic associated fatty liver disease (MAFLD).Nonalcoholic steatohepatitis (NASH) is a progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma.Currently there are no approved drugs available for NAFLD/NASH treatment. Glucagon-like peptide-1 (GLP-1) receptor agonist not only reverses the progression of NAFLD indirectly through an incretin effect that improves key metabolic parameters involved in NAFLD, but also has a direct effect on lipid metabolism, inflammation and oxidative stress of hepatocytes. Herein, this study reviews the effects and potential mechanisms of GLP-1 receptor agonists on nonalcoholic fatty liver disease.